Immunotherapy offers hope for men with prostate cancer


Immunotherapy is a treatment procedure which enhances or supress the body’s immune system to fight against a disease. Immunotherapies which enhance the immune response are called as activation immunotherapies and those which reduce or suppress the immune response are called as suppression immunotherapies. Immunotherapy is of many types but the major immunotherapies for cancer include Monoclonal antibodies, Cancer vaccines and Non-specific immunotherapies.


The main aim of the Immunotherapy: Open Access is to publish high quality research works and provide Open Access to the articles using this platform. The Journal offers a rapid and time bound review and publication that freely disseminates research findings related to immunotherapy. Immunotherapy: Open Access Journal caters to the requirements of the medical practitioners, researchers, lab professionals, students, academicians, and industry that is involved in Medical and clinical studies. No matter how prestigious or popular; it increases the visibility and impact of published work. It increases convenience, reach, and retrieval power. Free online literature software facilitates full-text searching, indexing, mining, summarizing, translating, querying, linking, recommending, alerting, "mash-ups" and other forms of processing and analysis.

Immunotherapy: Open Access brings articles related to immunotherapeutic aspects such as Allergy Immunotherapy, Immunotherapy for Kidney Failure, melanoma Immunotherapy, Sublingual Immunotherapy, Immunotherapy for HIV, Immunotherapy for autoimmune diseases and transplantation, Biomarkers for cancer immunotherapy, Drug delivery systems and drug interactions, Novel immunotherapeutic agents, clinical trials for immunotherapy, Cancer immunotherapy, Prostate Cancer Immunotherapy, Lung Cancer Immunotherapy, Breast Cancer Immunotherapy, Pancreatic Cancer Immunotherapy, Bladder Cancer Immunotherapy, Ovarian Cancer Immunotherapy, Colon Cancer Immunotherapy, Cervical Cancer Immunotherapy, Immunotherapeutic Products

All works published by Longdom Publishing SL are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the work provided the original work and source is appropriately cited. Immunotherapy: Open Access strongly supports the Open Access initiative. All published articles will be assigned DOI provided by Cross Ref. Immunotherapy: Open Access Journal will keep up-to- date with latest advances in the field of immunotherapy. Abstracts and full texts (HTML, PDF and XML format) of all articles published by Immunotherapy: Open Access are freely accessible to everyone immediately after publication. The Journal supports the Bethesda Statement on Open Access Publishing.

The indexing of the journal includes RefSeek, EBSCO A-Z, Publons, Geneva Foundation for Medical Education and Research, OCLC- WorldCat.


Articles can be submitted at Editorial Tracking System which makes easy to track the paper for editors, authors as well as publishers. Editorial Board was formed with more than 30 eminent editors all over the world.


Journal provides:

  • 21 day rapid review process with international peer-review standards.
  • Timeline of processing from Submission to Publication is 45 days.
  • Manuscript will be published within 7days of acceptance.
  • Submit manuscript at online submission or send as an e-mail attachment to or

Media contact:


Sarah Eve

Managing Editor

Immunotherapy: Open access

Whatsapp No:  +1-504-608-2390